Can vitamin D improve symptoms and quality of life in people with irritable bowel syndrome (IBS)?
| ISRCTN | ISRCTN13277340 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN13277340 |
| Secondary identifying numbers | 016753 |
- Submission date
- 23/03/2018
- Registration date
- 25/04/2018
- Last edited
- 02/08/2021
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Digestive System
Plain English summary of protocol
Background and study aims
Irritable bowel syndrome (IBS) is a common condition that affects the digestive system. IBS is usually experienced for a life-time and symptoms include bloating, constipation, diarrhoea, and stomach cramps. These symptoms can affect a person for days, weeks or even months at a time. This can be a difficult condition to live with and can have a large impact on a person's everyday life. The cause of IBS is unknown, although it is thought to be associated with a family history of IBS, stress and certain foods. IBS cannot be cured but can often be managed with medication and dietary changes. Research has shown that people with IBS also have low levels of vitamin D. The aim of this study is to assess whether increasing vitamin D levels in people with IBS helps to improve their symptoms.
Who can participate?
Men and women aged between 18-60 years with a diagnosis of IBS
What does the study involve?
Each person will be put into one of two groups to receive either a vitamin D or placebo (dummy) supplement mouth spray to be taken each day for 12 weeks. All participants will be asked to fill in a total of seven Symptom Severity Questionnaires (SSS-IBS), two Quality of Life Questionnaires (QoL), and one Food Frequency Questionnaire (FFQ). All participants will have blood samples taken at the first and last appointment. This will be done with a finger prick blood test kit. All participants will take a mouth spray, only half of the volunteers will get the active (real) vitamin D supplement.
What are the possible benefits and risks of participating?
The supplement that participants will be taking are well under the advised limit, however, there is a very unlikely risk of vitamin D levels going too high. Side effects of excessive vitamin D levels include raised calcium blood levels, nausea and constipation. Participants will be monitored closely for any problems they may experience during the study. There will also be small risks involved with taking blood samples, such as pain around the site of
insertion, as with any blood test. These risks will be clearly explained to the participants. The finger prick only occurs twice; at the start and end of the 12 weeks. Volunteers on the active (real) supplement may benefit from their participation in the research as they may see an improvement in their symptoms and all volunteers will receive a £50.00 voucher as a thank you for their participation.
Where is the study run from?
This study will be run from the Medical School at the University of Sheffield.
When is the study starting and how long is it expected to run for?
Recruitment will occur three times over the next 2 years. The first two rounds will occur in the winter periods (Jan-Apr) in 2018 and 2019 in the local area with the goal of reaching 160 volunteers. A further recruitment will take place in 2019 to recruit volunteers from outside the local area and will use postal and online methods to complete the research. The anticipated start date of the trial is September 2018 and will run until September 2020.
Who is funding the study?
This research has been part funded by the University of Sheffield and by an industry partner BetterYou.
Who is the main contact?
The main person to contact regarding this study is Dr Bernard Corfe, Senior Lecturer in Oncology Principal Investigator in Molecular Gastroenterology, Fellow of Insigneo, b.m.corfe@sheffield.ac.uk.
Contact information
Scientific
The University of Sheffield
The Medical School
Beech Hill Road
Sheffield
S10 2RX
United Kingdom
Sheffield
S10 2RX
United Kingdom
Public
The Medical School
Beech Hill Road
Sheffield
S10 2RX
United Kingdom
Sheffield
S10 2RX
United Kingdom
| Phone | 07925034693 |
|---|---|
| cewilliams1@sheffield.ac.uk |
Study information
| Study design | Double-blind placebo-controlled two-arm parallel-design study |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised controlled trial |
| Study setting(s) | Home |
| Study type | Treatment |
| Participant information sheet | Not available in web format, please use contact details to request a participant information sheet. |
| Scientific title | To assess whether an increase of vitamin D in subjects with irritable bowel syndrome improves symptoms (D-IBS) |
| Study acronym | D-IBS |
| Study objectives | The hypothesis is that a 3000 IU vitamin D supplement will reduce symptom severity and improve quality of life compared with placebo in participants with IBS, based on self-reported outcomes. |
| Ethics approval(s) | University of Sheffield,19/12/2017, Registration number: 160216727, Reference Number: 016753 |
| Health condition(s) or problem(s) studied | Irritable bowel syndrome |
| Intervention | Patients administered 3000 IU (75 microg) vitamin D sublingual spray or placebo sublingual spray once daily for 12 weeks |
| Intervention type | Supplement |
| Primary outcome measure | Reduction in Total Symptom Severity for IBS, measured by visual analogue scale (VAS) at baseline and exit, and a cumulative measure taken fortnightly across the intervention period (weeks 0, 2, 4, 6, 8, 10, 12). |
| Secondary outcome measures | 1. Serum vitamin D concentrations will be assessed at baseline and exit: bloodspots will be taken and analysed by liquid chromatography-mass spectrometry . 2. Quality of life is assessed at baseline and exit using The Irritable Bowel Syndrome - Quality of Life questionnaire (IBS-QOL) |
| Overall study start date | 01/09/2017 |
| Completion date | 30/09/2020 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Sex | Both |
| Target number of participants | 160 |
| Total final enrolment | 135 |
| Key inclusion criteria | Clinical diagnosis of IBS using the ROME criteria and reaching severity score of 150 on SSS scale at time of recruitment. As some participants may have active IBS but historic diagnosis, no one version of ROME is specified as long as a clinical diagnosis was made at the time. |
| Key exclusion criteria | 1. Pregnant or lactating 2. Regular use of nutritional supplements 3. BMI >30 kg/m2 4. BMI <18 kg/m2 5. Any history of gastrointestinal disorders (Crohn’s disease, ulcerative colitis, diverticulitis) 6. Diabetes mellitus |
| Date of first enrolment | 08/01/2018 |
| Date of final enrolment | 30/07/2020 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centre
Beech Hill Road
Sheffield
S10 2RX
United Kingdom
Sheffield
S10 2RX
United Kingdom
Sponsor information
University/education
The Medical School
Beech Hill Road
Oncology and Metabolism
Sheffield
S10 2RX
England
United Kingdom
"ROR" |
https://ror.org/05krs5044 |
|---|
Funders
Funder type
Not defined
No information available
No information available
Results and Publications
| Intention to publish date | 30/09/2020 |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Data sharing statement to be made available at a later date |
| Publication and dissemination plan | Planned publication in a high-impact peer reviewed journal |
| IPD sharing plan | As there are no repositories for trial data, we will share an annotated, anonymised spreadsheet on request following publication of any papers. |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | 30/07/2021 | 02/08/2021 | Yes | No |
Editorial Notes
02/08/2021: Publication reference and total final enrolment added.
